HC Wainwright & Co. Reiterates Buy Rating on LENZ Therapeutics, Inc. (LENZ)

Market Context

LENZ Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $5.70 with a market capitalization of $684.1M. The stock has declined 83.7% over the past 52 weeks.

Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for LENZ Therapeutics, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for LENZ Therapeutics, Inc.

Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 07, 2026	HC Wainwright & Co.	Buy	N/A
May 13, 2026	Citigroup	Buy	N/A
May 12, 2026	HC Wainwright & Co.	Buy	N/A
May 12, 2026	Piper Sandler	Neutral	N/A
Apr 21, 2026	HC Wainwright & Co.	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View LENZ Stock Page